-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bimatoprost Grenod in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bimatoprost Grenod in Open-Angle Glaucoma Drug Details: Bimatoprost grenod (NCX-470) is...
-
Product Insights
NewOcular Hypertension – Drugs In Development, 2024
Empower your strategies with our Ocular Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea, and bleeding at...
-
Product Insights
NewOpen-Angle Glaucoma – Drugs In Development, 2024
Empower your strategies with our Open-Angle Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bimatoprost Grenod in Open-Angle Glaucoma Drug Details: Bimatoprost grenod (NCX-470) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mipasetamab Uzoptirine in Osteosarcoma Drug Details:ADCT-601(BGB-601) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bimatoprost Grenod in Open-Angle GlaucomaDrug Details: Bimatoprost grenod (NCX-470) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zimberelimab in Esophageal Cancer Drug Details:Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that...